Updated: Sep 03, 2023 22:36 IST
Study gives more insight into advanced form of thyroid cancer treatment
According to the findings of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Centre, adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not improve outcomes in patients with differentiated thyroid cancer (DTC), which develops from thyroid follicular cells.
Read more
हिंदी खबर